InnoCan Pharma's Waiting Game: SEC Review Drags On as Consumer Arm Hits New Milestones

InnoCan Pharma's NYSE American listing remains stuck in SEC limbo, but its Valitic brand hits 100K reviews and 2M customers, offsetting revenue dips and insider loan pressure.

The clock was supposed to run out on January 30, 2026. That was the target date InnoCan Pharma had set for its long-awaited listing on the NYSE American. Seven months later, the company remains stuck in regulatory limbo, still awaiting clearance from the U.S. Securities and Exchange Commission on its F-1 registration filing.

The paperwork has been amended multiple times, yet no fresh date has been set for the move. Management finds itself in an awkward holding pattern — one where the promise of an uplisting hangs in the balance while the company's day-to-day operations tell a somewhat different, more encouraging story.

The Consumer Side Keeps Delivering

Amid the listing uncertainty, the company's wellness division has been quietly stacking up wins. Valitic, the beauty and personal care brand housed under B.I. Sky Global — a joint venture in which InnoCan holds a 60 percent stake — has now surpassed 100,000 verified positive customer reviews across major U.S. online marketplaces.

Roni Kamhi, CEO of B.I. Sky Global, framed the figure as a vote of confidence, noting that the review count reflects customer trust and repeat recommendations. The milestone lands just days after Valitic crossed the 2 million customer threshold, marking the second notable achievement for the brand within a short window.

These aren't vanity metrics. The online sales segment — which develops, manufactures, and markets cosmetic products — accounts for the bulk of InnoCan's revenue, as confirmed in the first-quarter 2026 report. The consumer goods arm has effectively become the company's financial engine while the pharmaceutical pipeline matures.

The Funding Squeeze Behind the Scenes

That engine, however, is still running on fumes. InnoCan reported 2025 revenue of $26.6 million, down 9.6 percent from the $29.4 million posted the prior year. Management points to sequentially smaller declines and expects that trend to carry into the first quarter of 2026, but the wellness business hasn't yet achieved a definitive turnaround.

To bridge the gap, the company has leaned increasingly on short-term insider loans. April 2026 brought $200,000 from one financing round, quickly followed by an additional $450,000 with participation from new lender Tamar Innovest Limited. These notes carry a fixed annual interest rate of 10 percent and mature after twelve months — or upon completion of the U.S. offering under the F-1 registration, whichever comes first.

That structure creates a delicate dynamic. If the SEC approval drags on or the capital raise comes up short, the balance sheet pressure intensifies rather than dissipates. The terms of the raise itself remain undefined, contingent on both market conditions and regulatory sign-off.

Two Scenarios, One Tipping Point

For shareholders, the calculus is straightforward. A successful NYSE American listing would open the door to a far larger pool of U.S. investors, potentially improving both liquidity and valuation compared to the current over-the-counter trading and the Canadian CSE listing. The combination of a Nasdaq-adjacent venue and stabilizing revenue could spark a re-rating.

The bearish counterpoint is equally clear: if the listing stalls further or the offering must be priced at a steep discount, existing holders face meaningful dilution. The insider loans would then look less like a bridge and more like a trap.

On the operational front, there are genuine bright spots beyond the consumer milestones. The FDA's veterinary division has granted a fee waiver for the LPT-CBD product for the third consecutive time, and a peer-reviewed study in Frontiers in Veterinary Science confirmed the formulation's effectiveness in dogs with osteoarthritis.

What to Watch Next

Until the SEC resolves the F-1 filing, the share price is likely to trade on speculation about listing timing rather than fundamentals. The insider notes serve as a stopgap, not a sustainable financing solution.

The next concrete signal will be an updated F-1/A filing or formal confirmation of the NYSE American listing. That will reveal whether the process is genuinely advancing or remains stuck in the SEC's review loop. For now, InnoCan is a company with a consumer business firing on all cylinders and a capital markets strategy waiting for its green light.